TriSalus Life Sciences (TLSI) Net Cash Flow (2021 - 2026)

TriSalus Life Sciences (TLSI) has 6 years of Net Cash Flow data on file, last reported at $35.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 699.2% year-over-year to $35.8 million; the trailing twelve-month figure through Mar 2026 stood at $43.2 million (up 378.44% YoY), and the FY2025 full-year result was $11.9 million, up 466.36% from the prior year.
• Net Cash Flow for Q1 2026 stood at $35.8 million, up from -$2.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $35.8 million in Q1 2026 and bottomed at -$17.8 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$2.6 million (2023), against an average of $1.5 million.
• The widest annual swing landed in 2023, when Net Cash Flow plunged 15785.95%; it then jumped 699.2% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$2.7 million in 2022, then tumbled by 255.5% to -$9.5 million in 2023, then surged by 70.93% to -$2.8 million in 2024, then advanced by 18.64% to -$2.2 million in 2025, then soared by 1690.93% to $35.8 million in 2026.
• The last three Net Cash Flow figures came in at $35.8 million (Q1 2026), -$2.2 million (Q4 2025), and -$3.8 million (Q3 2025), per Business Quant data.

Peer Comparison